Zacks Equity Research highlights Crocs, Inc. (Nasdaq: CROX) as the Bull of the Day and ChoicePoint (NYSE: CPS) as the Bear of the Day. In addition, Zacks Equity Research provides analysis on Amgen, Inc. (Nasdaq: AMGN) and Caterpillar (NYSE: CAT). Full analysis of all these stocks is available at http://at.zacks.com/?id=2676.
Here is a synopsis of all four stocks:
Our Bull of the Day recommendation is for Crocs, Inc. (Nasdaq: CROX). We are upgrading CROX shares from Hold to Buy. The stock down 61% from its October peak, and it looks attractively valued at just 11.2x our 2008 EPS estimate. While we do not expect CROX to move back to previous high near $75 in the next few months, we do expect the stock to easily outperform the broader market. Our six-month target price is $44, which is 17x our 2008 EPS estimate and represents a P/E-to-growth ratio of just 0.85x. Crocs is scheduled to report fourth quarter results on February 20.
Our Bear of the Day recommendation is for ChoicePoint (NYSE: CPS). ChoicePoint has embarked on a strategy of internal growth and is focusing on its core business lines. We believe that over time, the company will be headed in the right direction. However, it will take time for these initiatives to show results, and in the meantime the company is facing declining revenues from its mortgage business that will likely persist for the next few quarters. We therefore maintain our Sell rating on CPS shares and lower our price target to $30.00.
Amgen, Inc. (Nasdaq: AMGN), a global biotechnology company, is focused on the development and commercialization of human therapeutics. The company's key products are Epogen/Aranesp (anemia), Neupogen/Neulasta (neutropenia) and Enbrel (inflammatory disease). Recent negative events surrounding lead product Aranesp have punished the shares greatly. Results in the third quarter demonstrate the challenging ESA market. Nevertheless, we still feel as though the pipeline is significantly undervalued, and we continue to recommend the name as a long-term Hold within the biotechnology sector. Our price target is $56.
Caterpillar (NYSE: CAT) reported fourth quarter EPS of $1.50, above the $1.32 reported a year ago, due to a lower share count, a reduction in SG&A and R&D costs, increased price realization, and higher International sales volume. Caterpillar plans to up FY08 R&D spending by 20% to support an investment in new products. Also, it plans to allocate capital to add capacity in growth markets outside the U.S. Our FY08 EPS estimate of $5.59 assumes 4% earnings growth. This forecast assumes continued strength in machine and engine sales to Africa, the Middle East, Asia-Pacific and Latin America, but a greater-than-anticipated slowdown in the U.S and Western European construction markets than CAT currently anticipates. Our target price is $68.00.
Get the full analysis of all these stocks by going to http://at.zacks.com/?id=2649.
About the Bull and Bear of the Day
Every day, the analysts at Zacks Equity Research select two stocks that are likely to outperform (Bull) or underperform (Bear) the markets over the next 3-6 months.
About the Analyst Blog
Updated throughout every trading day, the Analyst Blog provides analysis from Zacks Equity Research about the latest news and events impacting stocks and the financial markets.
About Zacks Equity Research
Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.
Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.
Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978 by Leonard Zacks. As a PhD in mathematics Len knew he could find patterns in stock market data that would lead to superior investment results. Amongst his many accomplishments was the formation of his proprietary stock picking system; the Zacks Rank, which continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros.
The performance of the Zacks Rank portfolios for annual and year-to-date periods are the linked monthly total returns (price changes + dividends) of equal weighted hypothetical portfolios, consisting of those stocks with the indicated Zacks Rank, assuming monthly rebalancing and zero transaction costs. These are not the returns of actual portfolios. The hypothetical portfolios were created at the beginning of each month from January 1988 forward based on the values of the Zacks Rank available to Zacks' clients before the beginning of each month. The portfolios created monthly from 1988 through September 2006 exclude ADRs and are comprised of stocks that have the indicated Zacks Rank and were covered by at least two analysts at the time of the stocks inclusion in the portfolio. Starting in October 2006 and going forward, the portfolios are comprised of all stocks with the indicated Zacks Rank and do not exclude ADRs, which is more reflective of the list of stocks that customers will find on the Zacks web sites. These performance numbers have been audited from 1995 through 2003 by Virchow, Krause & Company, LLP.